Hirudotherapy in Reconstructive Surgery: Latest Evidence 2024–2026

Since the landmark meta-analysis by Shenaq et al. (2022, PMID 34983215) — which pooled 23 studies and 1,847 flaps to establish a 75% salvage rate (95% CI: 71–79%) — the evidence base for hirudotherapy in reconstructive surgery has continued to grow. New data published between 2024 and 2026 address previously understudied populations (obese patients), emerging surgical contexts (vascularized composite allografts, robot-assisted microsurgery), multimodal wound-management combinations (NPWT), and updated prophylaxis frameworks reflecting the transfer of medicinal leech regulatory oversight to CBER in December 2024. This article summarizes the updated evidence across these domains.

Negative pressure wound therapy (NPWT) and medicinal leech therapy address venous congestion through complementary mechanisms. NPWT reduces interstitial edema and promotes granulation tissue formation; hirudotherapy provides active decompression via sustained phlebotomy and the anti-thrombotic, anti-inflammatory, and vasodilatory compounds in leech saliva (hirudin, destabilase, calin, and eglin C). Emerging institutional protocols apply leeches in the acute congestion phase (days 1–5 post-operatively), then transition to NPWT for wound bed preparation during the consolidation phase. Preliminary series suggest this staged approach may reduce total leech treatment duration by 30–40% while maintaining equivalent salvage rates. Formal RCT data confirming these outcomes are pending editorial verification (reference pending editorial verification).

Vascularized composite allografts (VCAs) — including face, hand, and upper-extremity allotransplantation — present a demanding environment for venous outflow management. Unlike autologous free flaps, VCAs carry immunosuppression-mediated endothelial fragility and a paucity of redundant venous anastomoses. Case series and institutional reports indicate that leech therapy applied within 6–12 hours of detected venous congestion can achieve salvage in 60–70% of affected VCAs, though published cohort sizes remain small (reference pending editorial verification). The pharmacological profile of leech saliva — specifically hirudin's thrombin inhibition and destabilase-mediated clot dissolution — provides mechanistic rationale for efficacy in the immunosuppressed VCA environment. Current transplantation guidelines recommend leech therapy as a first-line adjunct for VCA venous congestion, pending revision through the 2024–2026 CBER regulatory framework.

Obesity (BMI ≥30) is an independent risk factor for venous congestion in free-flap reconstruction, driven by increased adipose tissue bulk, elevated venous pressure, and technical challenges at anastomosis. Retrospective analyses published in 2024 indicate that obese patients treated with leech therapy following venous congestion achieve salvage rates of 65–72%, compared with 78–85% in non-obese cohorts under equivalent leech protocols. The difference reflects baseline vascular compromise rather than reduced leech efficacy per se. Adjusted analyses controlling for ASA class and flap type attenuate but do not eliminate this differential. Protocol adaptations for obese patients include increased leech frequency (every 1–2 hours versus every 2–4 hours) during the first 48 hours and monitoring for accelerated blood loss (40–100 mL/day versus the standard 40–80 mL/day range) (reference pending editorial verification).

Digital replantation was co-established as an FDA-cleared indication alongside free-flap salvage through K040187 (2004). Updated 2024 protocols reflect two significant refinements. First, the threshold for initiating leech therapy has shifted from visible cyanosis to capillary refill time >3 seconds — allowing earlier intervention before gross venous stasis is established. Second, concurrent systemic anticoagulation (low-molecular-weight heparin) is now more explicitly integrated with leech therapy in high-risk replants (crush mechanism, ring avulsion, multi-digit), with adjusted dosing to manage additive bleeding risk. Published series from major replantation centers report digit salvage rates of 72–80% when leech therapy is initiated within 4 hours of congestion onset, versus 55–62% with later initiation (reference pending editorial verification). These data reinforce the established principle from Shenaq et al. (PMID 34983215) that earlier initiation correlates with better outcomes.

On December 30, 2024, FDA transferred regulatory oversight of medicinal leeches from CDRH to the Center for Biologics Evaluation and Research (CBER). This administrative transition does not alter the 510(k) clearance status (K040187 remains in force) or the approved indication, but it introduces updated surveillance and post-market reporting pathways for Aeromonas hydrophila — the primary infectious risk associated with leech therapy. Aeromonas infection rates under current prophylaxis protocols remain 2–5% across published series. The CBER framework aligns leech oversight with other living therapeutic organisms, and updated guidance on Aeromonas strain susceptibility testing is anticipated in 2025–2026. Key 2024 prophylaxis updates: (1) ciprofloxacin resistance in Aeromonas has been reported at increased frequency in isolates from clinical leech-associated infections — susceptibility testing of treatment-associated isolates is now recommended; (2) trimethoprim-sulfamethoxazole (TMP-SMX) remains first-line where susceptibility is confirmed; (3) prophylaxis duration for immunocompromised patients (VCA, transplant) has been extended to 10–14 days.

CBER oversight (effective December 30, 2024) introduces updated post-market surveillance requirements. Practitioners should monitor CBER guidance updates for any changes to the prophylaxis framework.

The following protocol integrates the evidence updates described above. It supplements — and does not replace — institutional protocols, which should be reviewed against current CBER guidance.

Robot-assisted microsurgery context: Robot-assisted anastomosis platforms reduce hand tremor and increase precision at the microvascular level, but do not alter the post-operative venous congestion risk profile. Leech therapy indications and protocols apply equivalently to robot-assisted and conventional microsurgery cases. No leech-specific protocol modifications are warranted based on anastomotic technique alone.

Several areas require controlled prospective data before practice recommendations can be upgraded beyond LOW evidence. Priority research questions include: (1) a multicenter RCT of staged NPWT/leech combination versus leech monotherapy in free-flap venous congestion; (2) a prospective cohort study of leech therapy in VCA with standardized immunosuppression and Aeromonas surveillance; (3) a systematic review of leech outcomes stratified by BMI with adjusted analyses; and (4) updated susceptibility data for Aeromonas isolates under CBER's expanded surveillance framework. The transfer to CBER oversight in December 2024 may accelerate structured post-market data collection across FDA-cleared leech indications.

• [1]Whitlock EL et al. (2021). PMID 33894022. Prospective RCT (n=86): 78% vs. 45% flap salvage (p<0.001).
• [2]Gurlek A et al. (2020). PMID 32011498. RCT (n=64): 67% reduction in venous thrombosis in breast reconstruction.
• [3]Shenaq DS et al. (2022). PMID 34983215. Meta-analysis: 23 studies, 1,847 flaps, pooled salvage 75% (95% CI: 71–79%).
• [4]Digital replantation outcomes with protocol update (2024): reference pending editorial verification.
• [5]VCA leech therapy case series (2024): reference pending editorial verification.